STOCK TITAN
  1. Home
  2. Sec-filings
  3. PCRX
  4. [Form 4] Pacira BioSciences, Inc. Insider Trading Activity

Pacira BioSciences (PCRX) director receives RSU and stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Pacira BioSciences director Marcelo Bigal received new equity awards as part of compensation. He was granted 6,405 restricted stock units, each representing one share of common stock, which vest on June 10, 2027 if he remains in continuous service with the company.

He also received a stock option covering 10,891 shares of common stock at an exercise price of $23.42 per share. This option vests on June 10, 2027 under the same service condition and expires on June 10, 2036. Following the grant, his direct holdings of common stock total 17,798 shares.

Positive

  • None.

Negative

  • None.
Insider BIGAL MARCELO
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 10,891 $0.00 --
Grant/Award Common Stock 6,405 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 10,891 shares (Direct, null); Common Stock — 17,798 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.
RSU grant size 6,405 units Restricted stock units vesting June 10, 2027
Option grant size 10,891 shares Stock option covering common stock
Option exercise price $23.42 per share Stock option strike price
Option expiration June 10, 2036 Option term end date
Shares held after grant 17,798 shares Common stock directly held following transaction
Option vesting date June 10, 2027 Vesting contingent on continuous service
restricted stock units financial
"Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
continuous service financial
"provided that the reporting person remains in continuous service with the issuer through the vesting date"
contingent right financial
"Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BIGAL MARCELO
(Last)(First)(Middle)
C/O PACIRA BIOSCIENCES, INC.
2000 SIERRA POINT PARKWAY, SUITE 900
(Street)
BRISBANE CALIFORNIA 94005
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/10/2026A6,405(1)A$017,798D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$23.4206/10/2026A10,89106/10/2027(2)06/10/2036Common Stock10,891$010,891D
Explanation of Responses:
1. Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
2. The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.
Remarks:
/s/ Kristen Williams, Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Pacira BioSciences (PCRX) director Marcelo Bigal receive?

Marcelo Bigal received 6,405 restricted stock units and a stock option for 10,891 shares. Both awards were granted at no cost as part of compensation and are tied to future vesting conditions.

When do Marcelo Bigal’s new Pacira (PCRX) restricted stock units vest?

The 6,405 restricted stock units vest on June 10, 2027, if Marcelo Bigal remains in continuous service. Each unit represents the right to receive one share of Pacira common stock upon vesting.

What are the terms of Marcelo Bigal’s new Pacira (PCRX) stock option grant?

The stock option covers 10,891 shares at an exercise price of $23.42 per share. It vests on June 10, 2027, subject to continued service, and expires on June 10, 2036, if not exercised.

How many Pacira (PCRX) common shares does Marcelo Bigal hold after these grants?

After the equity grant, Marcelo Bigal directly holds 17,798 shares of Pacira common stock. This figure reflects his position following the award of 6,405 restricted stock units reported in the filing.

Are Marcelo Bigal’s Pacira (PCRX) equity awards open-market purchases?

No. The filing shows these are compensation-related grants, not open-market purchases. Both the restricted stock units and stock option were awarded at zero purchase price under the company’s equity programs.